Incyclix Bio seeks $100 million to support cancer studies. The company is developing a CDK2 inhibitor called INX-315.

Addition of the CDK 4/6 inhibitor improved progression-free survival by 15.2 months for patients with HR+/HER2+ advanced ...

The addition of a CDK 4/6 inhibitor to standard therapy in patients with "double-positive" metastatic breast cancer ...

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...

An analysis of secondary outcomes in the SONIA trial showed that adverse events with CDK4/6 inhibitors were similar ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

Patients with advanced estrogen receptor (ER)-positive breast cancer that progressed on CDK4/6 inhibitors had better survival ...

The efficacy data could help cushion Ibrance's losses of market share to Kisqali, a similar drug from Novartis.

Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic ...

"Abemaciclib had excellent tolerability and resulted in an improved PFS6 rate compared to historical controls in patients with recurrent or progressive high-grade meningiomas harboring NF2 or CDK ...

The POTAMI-61 study will involve two parts, with Part A enrolling approximately 20 subjects across two cohorts.